Medtronic plc
Financials
Valuation Metrics
Medtronic plc's Market Cap is $123.97B. At end of 2025 it was $123.16B. Ranked #125 of 3,116 in US market (top 4%), #85 of 1,644 on NYSE (top 5%), #6 of 203 in Health Care Equipment & Services (top 3%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $123.97B | US#125/3,116 Sec#6/203 |
| Revenue | $37.54B | US#171/3,116 Sec#14/203 |
| Net Income | $5.23B | US#142/3,116 Sec#6/203 |
| Total Assets | $93.31B | US#187/3,116 Sec#7/203 |
| Net Assets | $50.23B | US#88/3,116 Sec#6/203 |
| Employees | 95,000 | US#121/3,116 Sec#8/203 |
| Value | ||
| P/E | 23.70x | US#1,337/3,116 Sec#37/203 |
| P/B | 2.47x | US#1,529/3,116 Sec#70/203 |
| PEG | 1.94x | US#1,014/3,116 Sec#49/203 |
| P/S | 3.30x | US#1,839/3,116 Sec#123/203 |
| EV/EBITDA | 15.92x | US#1,609/3,116 Sec#63/203 |
| FCF Yield | 4.95% | US#1,399/3,116 Sec#61/203 |
| Profitability | ||
| ROE | 10.41% | US#1,321/3,116 Sec#66/203 |
| ROA | 5.61% | US#953/3,116 Sec#60/203 |
| Op. Margin | 18.08% | US#998/3,116 Sec#32/203 |
| Revenue Growth | 9.77% | US#1,270/3,116 Sec#87/203 |
| Earnings Growth | 12.21% | US#1,009/3,116 Sec#54/203 |
| Financial Health | ||
| Debt Ratio | 84.52% | US#934/3,116 Sec#93/203 |
| Total Debt | $28.15B | US#168/3,116 Sec#8/203 |
| FCF | $6.13B | US#136/3,116 Sec#8/203 |
| Cash | $1.69B | US#478/3,116 Sec#28/203 |
| Current Ratio | 2.07x | US#1,188/3,116 Sec#107/203 |
| Net Debt/EBITDA | 2.80x | US#1,549/3,116 Sec#96/203 |
| Dividend | ||
| Div. Yield | 2.94% | US#624/3,116 Sec#7/203 |
| Div. Growth | 8.63% | US#584/3,116 Sec#20/203 |
| Performance | ||
| 1Y Return | 6.92% | US#1,615/3,116 Sec#119/203 |
| 1M Return | 11.90% | US#607/3,116 Sec#63/203 |
| From 52W High | -8.53% | US#702/3,116 Sec#76/203 |
| 1Y MDD | -29.48% | US#1,269/3,116 Sec#61/203 |
| Trading | ||
| Volume | 5,513,784 shares | US#308/3,116 Sec#14/203 |
| Trading Value | $535M | US#188/3,116 Sec#12/203 |
| Per Share | ||
| EPS | $4.07 | US#831/3,116 Sec#46/203 |
| BPS | $39.13 | US#635/3,116 Sec#43/203 |
Company Info
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.